At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumour expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.
Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer
25th May 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?